CNTX Context Therapeutics Inc.: Net earnings per share for the last 12 months

Public company logo of Context Tx (CNTX)

Context Therapeutics (CNTX) relies on external contractors for protein synthesis and testing, maximizing the delegation of production and research. Complex patents and the capital-intensive nature of development protect the business from competitors. This chart of stock quotes reflects the EPS TTM dynamics, which currently stands at -66.30. A virtual management model minimizes the company's environmental impact.

Context Therapeutics Inc (CNTX): Earnings per share for the last twelve months from 02/11/2024 to 11/17/2026

CNTX (Context Tx): analytical breakdowns and indicator data

- company stock capitalization data:
Initial company analysis:Context Therapeutics, CNTX
Manufactured product of Context Therapeutics Inc

This indicator measures the percentage change in net earnings per share over a rolling twelve-month period, smoothing quarterly volatility to identify the long-term earnings trend. By analyzing the year-over-year EPS (TTM) comparison, investors assess the capitalization efficiency of Context Therapeutics (CNTX) developments in oncotherapy, forecasting the financial results from bringing endometrial and breast cancer treatments to market.